Current Research
Liver Transplantation for Cholangiocarcinoma: An Effective Therapy
Principal Investigator: Jason Schwartz, MD
Criteria for Eligibility into Study:
- Age <65
- Tumor diameter <= 4cm
- No spread to level 2 lymph nodes
Required Components for Eligibility into Study:
- ERCP
- Biopsy and pathology report showing Cholangiocarcinoma
- Imaging of chest, abdomen and pelvis might include:
- CT with IV contrast
- MRI
- MRCP
- PET/CT
Molecular Signature of Cholangiocarcinoma in Patients at Risk for
Hepatobiliary Malignancies
Principal Investigator: Jason Schwartz, MD
Co-Investigators: John Sorenson, MD; William Hutson, MD; Lisa Hazard, MD;
Kenneth Boucher, PhD; Philip Bernard, MD; Sean Mulvihill, MD;
Courtney Scaife, MD;, James Carlisle, MD; Joel Bentz, MD;
Douglas Adler, MD; Jason Wills, MD; Robert Wong, MD
Inflammatory Bowel Disease, Primary Sclerosing Cholangitis, and the Link
with Pancreatic Cancer and Tumors of Epithelial Origin
Principal Investigators: Triscia Martin, PA; Jason Schwartz, MD (sponsor)
Pending Research
Use of Low Dose Interferon-? in the Treatment of Tumors of Uncertain Malignant Potential
Co-Principal Investigators: Jason Schwartz, MD; William Hutson, MD; Lei Chen, MD, PhD
Co-Investigators: John Sorenson, MD; Timothy Gayowski, MD; Shaaban A, James Carlisle, MD; Triscia Martin, PA
Use of the LC Bead as a Radiosensitizer in Conjunction with Theraspheres to
Treat Nontransplantable Hepatic Malignancies
Principal Investigator: James Carlisle, MD
Co-Investigators: Jason Schwartz, MD; John Sorenson, MD; William Hutson, MD; Lisa Hazard, MD
Prospective, Randomized Trial of Ablative Therapies in Liver Cancer
Principal Investigators: James Carlisle, MD; Jason Schwartz, MD
Co-Investigators: John Sorenson, MD; William Hutson, MD; Timothy Gayowski, MD
Examination of JAG1 Expression in Cholangiocarcinoma as a Potential Prognostic Marker
Principal Investigators: Jason Schwartz, MD; Matthew Firpo, PhD
Co-Investigators: Lei Chen, MD, PhD
The Role of Tumor Accommodation in Undermining Host Surveillance Mechanisms
Principal Investigators: Jason Schwartz, MD
Co-Investigators: Robert Andtbacka, MD, CM; Lei Chen, MD, PhD
The Role of Abnormal Methylation in the Oncogenesis of Cirrhotic Livers
Principal Investigators: Timothy Gayowski, MD
Co-Investigators: Jason Schwartz, MD; Matthew Firpo, PhD; Lei Chen, MD, PhD
The Role of Phosphorylcholine Glycoproteins in the Immunomodulation of Hepatobiliary Malignancies
Principal Investigators: Jason Schwartz, MD; Lei Chen, MD, PhD
Co-Investigators: Matthew Firpo, PhD
Phototherapy for Unresectable Biliary Cancers
Principal Investigators: Jason Schwartz, MD; William Hutson, MD
A Trial Examining Standard Chemoembolization vs. Adriamycin-eluting Beads in
Combination with Standard Chemoembolization for Hepatocellular Carcinoma
and Unresectable Cholangiocarcinoma
Principal Investigators: James Carlisle, MD
Co-Investigators: Jason Schwartz, MD; William Hutson, MD; Timothy Gayowski, MD
A Trial Comparing Standard TACE with TACE Combined with Adriamycin-Eluting Beads for Liver Metastases
Principal Investigators: James Carlisle, MD
Co-Investigators: Jason Schwartz, MD; John Sorenson, MD; Timothy Gayowski, MD; Lei Chen, MD, PhD
A Trial Comparing Efficacy of Radiofrequency Ablation vs. Cryoablation for Primary and Recurrent Tumors of the Liver
Principal Investigators: James Carlisle, MD
Co-Investigators: Jason Schwartz, MD; William Hutson, MD; John Sorenson, MD; Timothy Gayowski, MD; Lei Chen, MD, PhD
TACE vs. Therasphere for HCC
Principal Investigators: James Carlisle, MD
Co-Investigators: Jason Schwartz, MD; William Hutson, MD; John Sorenson, MD; Timothy Gayowski, MD; Lei Chen, MD, PhD; Lisa Hazard, MD
A Trial Comparing RFA / Cryoablation vs. External Beam Radiation Therapy for Liver Metastases
Principal Investigators: James Carlisle, MD; Lisa Hazard, MD
Co-Investigators: Jason Schwartz, MD; William Hutson, MD; John Sorenson, MD; Timothy Gayowski, MD; Lei Chen, MD, PhD
The Use of MRCP as a Screening Modality in IBD Patients
Principal Investigators: James Carlisle, MD; Jason Schwartz, MD; William Hutson, MD
Co-Investigators: John Sorenson, MD; Timothy Gayowski, MD
A Trial Comparing Y90 vs. TACE for Metastases to the Liver
Principal Investigators: James Carlisle, MD; Lisa Hazard, MD
Co-Investigators: Jason Schwartz, MD; John Sorenson, MD; Timothy Gayowski, MD; William Hutson, MD
Y90 vs. TACE for Unresectable Cholangiocarcinoma
Principal Investigators: James Carlisle, MD; Lisa Hazard, MD; Jason Schwartz, MD
Co-Investigators: John Sorenson, MD; Timothy Gayowski, MD; William Hutson, MD
A Trial Examining the Role of Systemic Chemotherapy +/- Y90 as First Line Therapy for Colorectal Metastases to the Liver
Principal Investigators: Lei Chen, MD, PhD; Lisa Hazard, MD; James Carlisle, MD
Co-Investigators: Jason Schwartz, MD; John Sorenson, MD; Timothy Gayowski, MD; William Hutson, MD
A Trial Examining the Role of Systemic Chemotherapy +/- Y90 as First Line Therapy for Noncolorectal Metastases to the Liver
Principal Investigators: Lei Chen, MD, PhD; Lisa Hazard, MD; James Carlisle, MD
Co-Investigators: Jason Schwartz, MD; John Sorenson, MD; Timothy Gayowski, MD; William Hutson, MD
TACE +/- Sorafenib for Large, Unresectable HCC
Principal Investigators: James Carlisle, MD; Lei Chen, MD, PhD
Co-Investigators: Jason Schwartz, MD; John Sorenson, MD; Timothy Gayowski, MD; William Hutson, MD
TACE +/- Sorafenib for Nontransplantable, Nonresectable, Moderate-Sized HCC
Principal Investigators: James Carlisle, MD; Lei Chen, MD, PhD
Co-Investigators: Jason Schwartz, MD; John Sorenson, MD; Timothy Gayowski, MD; William Hutson, MD
TACE +/- Sorafenib for Transplantable HCC
Principal Investigators: Jason Schwartz, MD: James Carlisle, MD; Lei Chen, MD, PhD
Co-Investigators: John Sorenson, MD; Timothy Gayowski, MD; William Hutson, MD
TACE/Y90 followed by PVE for Resectable Hepatic Tumors
Principal Investigators: James Carlisle, MD; Jason Schwartz, MD
Co-Investigators: John Sorenson, MD; Timothy Gayowski, MD; William Hutson, MD
Characterization of a Transgenic Mouse Model of De Novo HCC
Principal Investigators: Wang L, Jason Schwartz, MD
Co-Investigators: Matthew Firpo, PhD; Philip Bernard, MD
Use of the LC Bead to Treat Nontransplantable Hepatic Malignancies
Principal Investigator: James Carlisle, MD
Co-Investigators: Jason Schwartz, MD
Use of the LC Bead to Downstage Hepatocellular Carcinoma for Transplant
Principal Investigator: James Carlisle, MD
Co-Investigators: Jason Schwartz, MD
Use of Global Positioning To Measure HCC Tumor Response to External Beam Radiation
Principal Investigator: Lisa Hazard, MD
Use of Palliative Chemoradiation in Unresctable Cholangiocarcinoma
Principal Investigator: Lisa Hazard, MD
Co-Investigators: James Carlisle, MD; Jason Schwartz, MD
|
